Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers
Article Abstract:
The effect of lopinavir/ritonavir (LPV/r) administration on cytochrome P450 (CYP) enzyme activity was quantified using a phenotyping biomarker cocktail study in healthy volunteers. LPV/r therapy results in modest induction of CYP1A2 and CYP2C9 and potent induction of CYP2C19 activity and it is also found that LPV/r inhibited intestinal CYP3A to a greater extent than hepatic CYP3A activity.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics
Article Abstract:
A study is discussed to evaluate the drug interaction between fosamprenavir (FPV) and esomeprazole (ESO) after repeated doses in healthy adults. Results reveal that simultaneous coadministration of ESO 20 mg qd with either FPV 1400 mg bid or FPV 700 mg bid + RTV 100 mg bid had no effect on steady-state amprenavir pharmacokinetics.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Protecting special interests in the name of "good science". The Pandemic and All-Hazards Preparedness Act: Improving public health emergency response
- Abstracts: Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction
- Abstracts: Biochemical markers for the prediction of preterm birth. Racial inequalities in preterm delivery: Issues in the measurement of psychosocial constructs
- Abstracts: Genomic signatures to guide the use of chemotherapeutics. Aurora kinases dawn as cancer drug targets. Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic liver damage in mice
- Abstracts: VX-680, a potent and selective small-molecule inhibitor of the Aurora-kinases, suppresses tumor growth in vivo